Abalone Bio (YC W20) — We create activating antibodies to treat diseases others can’t
Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs) + Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech. + Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. + Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.
Abalone Bio is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: We create activating antibodies to treat diseases others can’t. The founders listed are Richard Yu (Founder), Gustavo Pesce (Founder) (Y Combinator directory entry, March 11, 2020).
Get an email when Abalone Bio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year.
+ High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs)
+ Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech.
+ Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value.
+ Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.
Richard Yu
Founder
Gustavo Pesce
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 60 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Abalone Bio?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Abalone Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abalone Bio covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Abalone Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
